Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation
D. Melck et al., Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation, ENDOCRINOL, 141(1), 2000, pp. 118-126
Anandamide and 2-arachidonoylglycerol (2-AG), two endogenous ligands of the
CB1 and CB2 cannabinoid receptor subtypes, inhibit the proliferation of PR
L-responsive human breast cancer cells (HBCCs) through down-regulation of t
he long form of the PRL receptor (PRLr). Here we report that 1) anandamide
and 2-AG inhibit the nerve growth factor (NGF)-induced proliferation of HBC
Cs through suppression of the levels of NGF Trk. receptors; 2) inhibition o
f PRLr levels results in inhibition of the proliferation of other PRL-respo
nsive cells, the prostate cancer DU-145 cell line; and 3) CB1-like cannabin
oid receptors are expressed in HBCCs and DU-145 cells and mediate the inhib
ition of cell proliferation and Trk/PRLr expression. P-NGF-induced HBCC pro
liferation was potently inhibited (IC50 = 50-600 nM) by the synthetic canna
binoid HU-210, 2-AG, anandamide, and its metabolically stable analogs, but
not by the anandamide congener, palmitoylethanolamide, or the selective ago
nist of CB2 cannabinoid receptors, BML-190. The effect of anandamide was bl
ocked by the CB1 receptor antagonist, SR141716A, but not by the CB2 recepto
r antagonist, SR144528. Anandamide and HU-210 exerted a strong inhibition o
f the levels of NGF Trk receptors as detected by Western immunoblotting; th
is effect was reversed by SR141716A. When induced by exogenous PRL, the pro
liferation of prostate DU-145 cells was potently inhibited (IC50 = 100-300
nM) by anandamide, 2-AG, and HU-210. Anandamide also down-regulated the lev
els of PRLr in DU-145 cells. SR141716A attenuated these two effects of anan
damide. HBCCs and DU-145 cells were shown to contain 1) transcripts for CB1
and, to a lesser extent, CB2 cannabinoid receptors, 2) specific binding si
tes for [H-3]SR141716A that could be displaced by anandamide, and 3) a CB1
receptor-immunoreactive protein. These findings suggest that endogenous can
nabinoids and CB1 receptor agonists are potential negative effecters of PRL
- and NGF-induced biological responses, at least in some cancer cells.